CD19 and Burkitt lymphoma: IL-6 KD in anti-CD19 CAR T cells against Burkitt’s Lymphoma resulted in no objective neurotoxicity, immunotoxicity, or tumorigenicity, while retaining the anti-tumor cytotoxicity and production of other cytokines.